Sex: F
Vaccine: COVID19, VARZOS, VARZOS
Symptoms: Arthralgia, Back pain, Fatigue, Inappropriate schedule of product administration, Multiple sclerosis
Clinical narrative: November and December 2020 received the first and second doses for both, the Shingrix; Since November 2020 / worsening MS symptoms / pseudo or mini MS exacerbations; More back pain / worsening soon after each injection; More fatigue / worsening soon after each injection; More muscle pain / worsening soon after each injection; More joint pain / worsening soon after each injection; This case was reported by a consumer via call center representative and described the occurrence of ms aggravated in a 74-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis and COVID-19 VACCINE ASTRAZENECA for prophylaxis.   The patient's past medical history included multiple sclerosis (prior to starting Nucala). Previously administered products included Nucala with an associated reaction of multiple sclerosis (received a dose in June 2020 and got worsening pseudo or mini multiple sclerosis symptoms. For the tolerance of a dose, refer linked case US2021137243).   In December 2020, the patient received the 2nd dose of Shingrix. In November 2020, the patient received the 1st dose of Shingrix and the 1st dose of COVID-19 VACCINE ASTRAZENECA. In November 2020, not applicable after receiving Shingrix and less than a month after receiving Shingrix, the patient experienced ms aggravated (serious criteria GSK medically significant), back pain aggravated, fatigue aggravated, myalgia aggravated and arthralgia aggravated. In December 2020, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the ms aggravated, back pain aggravated, fatigue aggravated, myalgia aggravated, arthralgia aggravated and drug dose administration interval too short were unknown.   It was unknown if the reporter considered the ms aggravated, back pain aggravated, fatigue aggravated, myalgia aggravated and arthralgia aggravated to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported, but it could be 73 or 74 years. The patient reported that, she started Nucala around June 2020.  She has the powder for injection given to her at an infusion center.   The patient had noticed since November 2020, that when she got the Nucala injection and 1st dose of Shingrix and Covid 19 vaccine, she got worsening multiple sclerosis symptoms.  Her physician as said that she was having pseudo or mini multiple sclerosis exacerbations with the Nucala shot.  She had noticed more back pain, more fatigue, muscle pain and joint pain.  The patient said that, she just noticed some worsening soon after each injection.  In December 2020, the patient received the second dose of Shingrix earlier than the recommended schedule which led to shortening of vaccination schedule. The patient also received 2nd dose of Covid vaccine (AstraZeneca) in December 2020.  The patient had noticed that, her symptoms of worsening multiple sclerosis had considerably worsened after getting the Nucala shot in the year of reporting 2021.  The symptoms of worsening multiple sclerosis symptoms were considerably less severe last year from the date of reporting before she received the Shingrix and Covid vaccines. It was unknown if the reporter considered the ms aggravated, back pain aggravated, fatigue aggravated, myalgia aggravated and arthralgia aggravated to be related to Covid 19 vaccine. The reporter consented to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021137243:Pharma case (nucala)